Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Direct Meds vs NuuVim

Direct Meds
Graded #19

Higher grade

vs+11.5
NuuVim
Graded #101

Lower grade

The verdict

Direct Meds takes it — 82.6/100 to 71.1/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +12
85
97
Dose & formulationNuuVim +8
88
96
Clinical oversightDirect Meds +38
80
42
Labs & monitoringDirect Meds +28
78
50
FulfillmentDirect Meds +19
80
61
Contract termsDirect Meds +25
80
55
Direct Meds · left barNuuVim · right bar

The numbers

MetricDirect MedsNuuVim
WeighScore82.6/10071.1/100
GradeB−C
Scorecard rank#19#101
Semaglutide$179/mo$79/mo (all doses, compounded)
Tirzepatide$224/mo$133/mo (all doses, compounded)
CoverageNot publicly listedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed
NuuVim

Graded #101 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • No founder, CEO, medical director, or pharmacist-in-charge named
  • Refund and cancellation policy not surfaced on the site
  • Compounded medications are not FDA-approved
  • Doesn't disclose which pharmacy fills which drug or form
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard